Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Cangene Corporation.
Recruitment status was  Active, not recruiting
Information provided by:
Cangene Corporation Identifier:
First received: February 25, 2011
Last updated: March 8, 2011
Last verified: March 2011
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2011
  Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)